Low-Dose Bevacizumab and Atezolizumab Combined With TACE-HAIC in Unresectable Hepatocellular Carcinoma

NCT07543510 · clinicaltrials.gov ↗

NA

Phase

NOT_YET_RECRUITING

Status

38

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma
Atezolizumab Plus Bevacizumab
Transarterial Chemoembolization

Interventions

DRUG: TACE-HAIC + Atezolizumab + Low-dose Bevacizumab

Sponsor

Third Affiliated Hospital, Sun Yat-Sen University